Evommune (EVMN) Interest & Investment Income (2024 - 2026)

Evommune (EVMN) has reported Interest & Investment Income for 3 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest & Investment Income rose 272.59% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $5.2 million (changed N/A YoY), while the FY2025 annual figure was $3.3 million, up 2.5% from the prior year.
• Interest & Investment Income rose to $2.3 million in Q1 2026 per EVMN's latest filing, from $1.4 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $2.3 million in Q1 2026 and bottomed at $613000.0 in Q1 2025.
• Historically, Interest & Investment Income has averaged $1.1 million across 3 years, with a median of $794500.0 in 2024.
• Annual changes were most pronounced in 2025 — Interest & Investment Income surged 39.48% — and 2026, when it surged 272.59%.
• Evommune's Interest & Investment Income stood at $727000.0 in 2024, then soared by 98.49% to $1.4 million in 2025, then surged by 58.28% to $2.3 million in 2026.
• Business Quant data shows EVMN's Interest & Investment Income at $2.3 million in Q1 2026, $1.4 million in Q4 2025, and $862000.0 in Q3 2025.